Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose-Finding Study for the CBP / β-catenin Inhibitor OP-724 in Patients With Primary Biliary Cholangitis (Phase I)

NCT04047160 is registered in ClinicalTrials.gov with Kiminori Kimura, MD as lead sponsor.

NCT NCT04047160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04047160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose-Finding Study for the CBP / β-catenin Inhibitor OP-724 in Patients With Primary Biliary Cholangitis (Phase I)
Lead sponsor
Kiminori Kimura, MD
Phase
Phase 1
Overall status
Completed
Start date
August 29, 2019
Completion date
March 31, 2022
Enrollment
7 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

liver cirrhosis, biliary, primary biliary cholangitis (pbc)